The submission of a clinical protocol to the FDA and the initiation of a pre-clinical study in glioblastoma are critical steps in drug development. This news indicates CytoDyn's progress in expanding its research pipeline, which could positively impact investor sentiment and the company's valuation in the short term. The focus on glioblastoma, a challenging and unmet medical need, further enhances the potential significance of this development.